From Yahoo Finance: 2025-06-04 07:33:00

Agenus partners with Zydus Lifesciences in a $141m deal to advance clinical developments and manufacturing globally. Agenus will receive $75m upfront and up to $50m in contingent payments for botensilimab and balstilimab. Zydus plans to launch a BioCDMO business using Agenus’ facilities in the US for biologics contract manufacturing services.

Zydus will be the exclusive BioCDMO customer for Agenus, ensuring the biologics license application and launch readiness needs are met effectively. Zydus gains an exclusive license for the development and commercialization of BOT and BAL in Sri Lanka and India, paying a 5% royalty on net sales within those countries.

Zydus will also make an equity investment in Agenus by purchasing 2.1 million common stock shares. This $16m in gross proceeds will be used for working capital and accelerating clinical development and potential commercialization related to BOT/BAL. The partnership between Agenus and Zydus aims to advance cancer immunotherapy globally.

Agenus CEO Dr. Garo Armen highlights the confidence in Indian-American relations and the need for secure biopharma supply chains. The partnership with Zydus will accelerate future clinical trials for BOT/BAL and enhance Agenus’ global footprint in oncology therapeutics. The collaboration aims to advance cancer immunotherapy in India and internationally.

Read more: Agenus and Zydus sign agreements for botensilimab and balstilimab